Who is sponsoring NCT05762562?

NCT05762562 is sponsored by Istituti Clinici Scientifici Maugeri SpA.

What drugs are being tested in NCT05762562?

Interventions in NCT05762562: Telerehabilitation with open source platforms.

What condition does NCT05762562 study?

NCT05762562 studies Parkinson Disease.

Is NCT05762562 still recruiting?

NCT05762562 is currently completed. Last updated 9 March 2023.

Last reviewed 2023-03-09 · How we verify

NCT05762562

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Parkinson Disease Telerehabilitation Program (PDTR): a Home-motor Program. A Pilot Study.

Completed Last updated 9 March 2023

What this trial tests

trial testing Telerehabilitation with open source platforms in Parkinson Disease in 33 participants. Completed in 28 February 2022.

Timeline

1 February 2021

Primary endpoint
28 February 2022

28 February 2022

Quick facts

Lead sponsor	Istituti Clinici Scientifici Maugeri SpA
Status	Completed
Study type	OBSERVATIONAL
Enrollment	33
Start date	1 February 2021
Primary completion	28 February 2022
Estimated completion	28 February 2022
Sites	1 location across Italy

Drugs / interventions tested

Telerehabilitation with open source platforms

Conditions studied

Parkinson Disease — all drugs for Parkinson Disease →

Sponsor

Istituti Clinici Scientifici Maugeri SpA

Who can join

Adults 18 to 80, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Parkinson's disease (PD) leads to multifactorial disabilities with consequent social restrictions, especially in the COVID-19 era. Continuity of care, especially rehabilitation measures, is critical to improve or maintain an adequate QoL for patients. The Parkinson Disease Telerehabilitation Program (PDTR) is an individualized home rehabilitation program using open-source platforms (OSp). The main purpose of this pilot study is to investigate the feasibility of TR in patients with PD by using free OS platforms (PDTR PROGRAM). The target of this study was to have at least 90% of participants completing the program. To complete the program every single patient had to complete at least 80% of the prescribed TR sessions.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting

Other Istituti Clinici Scientifici Maugeri SpA trials

Trials by the same sponsor.

NCT07521436 — Awareness of Risk Factors and Perception of Cardiovascular Risk in Secondary Prevention Among Women and Men · not yet recruiting
NCT07451977 — Effects of Oxygen Supplementation During the 6-Minute Walk Test in Chronic Respiratory Failure or Exertional Hypoxemia · NA · recruiting
NCT07448181 — Real-life Ecological Momentary Assessment of Lived Burden in Hereditary AngioEdema · recruiting
NCT07432204 — Therapeutic Music Listening in Post Stroke Patients. · NA · recruiting
NCT07399418 — TRIAD - Tracking Risk in Integrated Alzheimer's Diagnostics. · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05762562 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Istituti Clinici Scientifici Maugeri SpA
Last refreshed: 9 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05762562.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing